[BIS] ProShares UltraShort Nasdaq Biotech

Overview

Type of security: Fund

Tags: Biotech, Country, Equity, ETF, Health care, Index Based, Inverse, Inverse 2X, Leveraged, Stocks, U.S.

The data is delayed by 15 minutes.

 

Price: 33.23 Change: -1.53 (-4.4%)
Ext. hours: Change: 0 (0%)

chart BIS

Refresh chart

Strongest Trends Summary For BIS

BIS is in the long-term down -56% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index®. The fund invests in derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times the inverse (-2x) of the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. It is non-diversified.

See how to gain 20% in 14 sec with TrendsInvesting

Technical Data
High 52 week23.44 Low 52 week15.58 Last close18.09 Last change1.29%
RSI47.76 Average true range0.67 Beta-2.14 Volume98.74 K
Simple moving average 20 days-0.77% Simple moving average 50 days-0.29% Simple moving average 200 days0.14%
Performance Data
Performance Week-1.15% Performance Month2.26% Performance Quart-2.79% Performance Half6.04%
Performance Year-19.92% Performance Year-to-date-7.28% Volatility daily2.21% Volatility weekly4.94%
Volatility monthly10.13% Volatility yearly35.1% Relative Volume183.77% Average Volume61.69 K
New High New Low
Funds Characteristics
30-day SEC yield Average market capitalization Average weighted market capitalization Forward P/E
Gross expense ratio2.91% Index dividend yield Median market cap Number of holdings
Price to Book Value Price to Earnings Total expense ratio0.95% Total net assets43.26 M
Weighted market capitalization

Info

Characteristics:
NAME VALUE
Gross Expense Ratio2,91
Total Expense Ratio0,95
Total Net Assets43.26 million
Top Holdings:
NAME VALUE
Amgen Inc.8,92
Biogen Idec Inc.8,05
Celgene Corp.7,79
Gilead Sciences Inc.7,68
Alexion Pharmaceuticals Inc.6,79
Regeneron Pharmaceuticals Inc.4,05
Vertex Pharmaceuticals Inc.3,92
Illumina Inc.3,89
Biomarin Pharmaceutical Inc.2,37
Incyte Corp.2,14
Sector Breakdown:
NAME VALUE
Biotechnology74,47
Pharmaceuticals22,61
Health Care Products2,54
Diversified0,24
Commercial Services0,14

News

2019-06-25 10:44:11 | Investing Strategies for Market Crashes

2019-01-15 12:49:24 | Top Performing Health Care ETFs of 2018

2018-09-20 18:46:00 | BlackChain Announces Consolidation and Name Change

2018-08-29 08:30:00 | BlackChain Announces Letter of Intent for 'Cold Chain' Tracking Business and Technology IoT, Consolidation and Private Placement

2018-08-08 08:30:00 | BlackChain Acquires Digital Asset Exchange Platform

2018-04-26 08:15:00 | BlackChain Solutions Inc. Signs LOI With DMG Blockchain Solutions Inc. to Bring P2P Lending to the Cryptocurrency Market

2017-05-01 12:57:00 | BlackIce Launches New Website and Media to Support U.S. Focus

2016-11-15 08:30:00 | BlackIce Commences Development of BESTTM its Next Generation Stress-Testing Tool

2016-10-17 10:10:02 | ETFs to Play as Biotech Juggles Election & Earnings

2016-10-14 15:26:44 | Can Biotech Stocks Stay “Trendy”?

2016-10-12 11:40:03 | How to Trade the Oil Rush with ETFs

2016-10-12 09:41:01 | Energy Momentum and Inverse Biotech: Two ETFs Trading with Outsized Volume

2016-09-06 09:25:00 | BlackIce Announces Corporate Update

2016-07-26 02:15:11 | Bisalloy Steel Group Ltd. :BIS-AU: Earnings Analysis: For the six months ended December 31, 2015 : July 26, 2016

2016-06-30 18:33:24 | Biotechs Building Base?...Or Bursting Bubble?

2016-06-28 08:00:00 | 5 Investing Strategies if the Market Crashes HDGE, BIS

2016-06-27 15:30:32 | As Brussels Overreaches and Brits Wave Goodbye, What to Buy Now

2016-06-27 08:21:58 | This Currency ETF Could Get Some Post-Brexit Love

2016-06-07 00:33:52 | Biotech Bounce: Sizzle Or Fizzle?

2016-05-20 08:38:08 | No CROC: This Currency ETF Could Shine

2016-05-11 09:08:13 | An ETF Rarity: Leveraged Bear ETFs Hauling In More Cash Than Bull Rivals

2016-05-03 12:01:00 | BIS vs. TQQQ: Comparing Leveraged NASDAQ ETFs

2016-04-28 15:26:38 | This Indicator Is Still Flashing A Bear Market Warning

2016-04-18 11:56:03 | How to Profit from the Failed Doha Meeting via ETFs

2016-03-30 11:04:00 | BlackIce Completes the Implementation of Basel II Using the ERA Solution with Vietnam International Bank VIB

2016-03-28 09:30:01 | Zacks Investment Ideas feature highlights: VelocityShares 3x Inverse Crude Oil ETN, ProShares UltraShort Bloomberg Crude Oil, Direxion Daily Energy Bear 3X ETF, ProShares UltraShort Oil & Gas and ProShares Short Oil & Gas

2016-03-01 12:03:05 | Top ETF Stories of February

2016-02-25 10:11:03 | Six Ways to Short Financial Stocks with ETFs

2016-02-24 11:54:04 | Forget Production Cut: Short Oil & Energy ETFs

2016-02-12 09:30:02 | Zacks Investment Ideas feature highlights: ProShares UltraShort Bloomberg Crude Oil, Direxion Daily FTSE China Bear 3X ETF, Direxion Daily Gold Miners Bull 3X ETF, Direxion Daily Financial Bear 3X ETF and Direxion Daily Emrg Mkts Bear 3X ETF

2016-02-09 09:56:00 | BlackIce Implements First Vietnam RWA Calculator

2015-12-08 04:12:36 | Is Inventure Foods Inc SNAK A Good Stock To Buy?

2015-11-29 18:14:15 | Cidara Therapeutics Inc CDTX: Are Hedge Funds Right About This Stock?

2015-11-27 09:17:26 | Should You Buy TESSCO Technologies, Inc. TESS?

2015-11-24 11:55:20 | How Do Hedge Funds Feel About ProShares UltraShort Nasdaq Biotech BIS?

2015-11-13 07:30:02 | Charts Are Looking up for Biotech ETFs